Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 6/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 5/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | TDO2 | P48775 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12164568 | 0.91 | MAP2K1 (0.53) | MAP2K1MAP2K2BRAFEIF2AK3NUDT1 | |
| SCHEMBL2564946 | 0.86 | MAP2K1 (0.51) | MAP2K1BRAFEIF2AK3KDM4E | |
| SCHEMBL12164588 | 0.85 | MAP2K1 (0.77) | MAP2K1MAP2K2 | |
| SCHEMBL4412075 | 0.84 | MAP2K1 (0.51) | MAP2K1MAP2K2NUDT1IDO1 | |
| SCHEMBL2566005 | 0.84 | MAP2K1 (0.72) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL2563035 | 0.84 | MAP2K1 (0.56) | MAP2K1IDO1TDO2 | |
| SCHEMBL5010174 | 0.83 | MAP2K1 (0.56) | MAP2K1BRAFEIF2AK3KDM4EMEN1 | |
| SCHEMBL4989997 | 0.82 | MAP2K1 (0.59) | MAP2K1MAP2K2BRAFEIF2AK3NUDT1 | |
| SCHEMBL14294807 | 0.82 | MAP2K1 (0.43) | MAP2K1MAP2K2NUDT1IDO1 | |
| SCHEMBL4986447 | 0.81 | MAP2K1 (0.54) | MAP2K1MAP2K2BRAFEIF2AK3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | MAP2K1 10/4885MAP2K2 3/4885BRAF 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.